Ibrolipim (BioDeep_00000839687)

   


代谢物信息卡片


Ibrolipim

化学式: C19H20BrN2O4P (450.03439900000006)
中文名称:
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: BrC1=CC(C#N)=C(C=C1)NC(C2=CC=C(C=C2)CP(OCC)(OCC)=O)=O
InChI: InChI=1S/C19H20BrN2O4P/c1-3-25-27(24,26-4-2)13-14-5-7-15(8-6-14)19(23)22-18-10-9-17(20)11-16(18)12-21/h5-11H,3-4,13H2,1-2H3,(H,22,23)

描述信息

D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents > D008082 - Lipotropic Agents
C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent
D020536 - Enzyme Activators > D058867 - Lipoprotein Lipase Activators
D009676 - Noxae > D000963 - Antimetabolites
Ibrolipim (NO-1886) is an orally active lipoprotein lipase (LPL)-promoting agent. Ibrolipim decreases plasma triglycerides, increases high-density lipoprotein cholesterol levels. Ibrolipim has renoprotective and hypolipidemic effects[1][2][3].

同义名列表

2 个代谢物同义名

Ibrolipim; NO-1886



数据库引用编号

6 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Yi Liu, Hongguang Li, Shuzhi Wang, Weidong Yin, Zongbao Wang. Ibrolipim attenuates early-stage nephropathy in diet-induced diabetic minipigs: Focus on oxidative stress and fibrogenesis. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2020 Sep; 129(?):110321. doi: 10.1016/j.biopha.2020.110321. [PMID: 32535382]
  • Werner J Geldenhuys, Joel Caporoso, Thomas C Leeper, Yoon-Kwang Lee, Li Lin, Altaf S Darvesh, Prabodh Sadana. Structure-activity and in vivo evaluation of a novel lipoprotein lipase (LPL) activator. Bioorganic & medicinal chemistry letters. 2017 01; 27(2):303-308. doi: 10.1016/j.bmcl.2016.11.053. [PMID: 27913180]
  • Masataka Kusunoki, Kazuhiko Tsutsumi, Daisuke Sato, Aki Nakamura, Satoshi Habu, Yuichi Mori, Munehiko Morishita, Takayuki Yonemoto, Tetsuro Miyata, Yutaka Nakaya, Takao Nakamura. Pioglitazone-induced body weight gain is prevented by combined administration with the lipoprotein lipase activator NO-1886. European journal of pharmacology. 2011 Oct; 668(3):486-91. doi: 10.1016/j.ejphar.2011.07.030. [PMID: 21835171]
  • Masataka Kusunoki, Kazuhiko Tsutsumi, Daisuke Sato, Aki Nakamura, Satoshi Habu, Yuichi Mori, Munehiko Morishita, Takayuki Yonemoto, Tetsuro Miyata, Yutaka Nakaya, Takao Nakamura. Activation of lipoprotein lipase increases serum high density lipoprotein 2 cholesterol and enlarges high density lipoprotein 2 particles in rats. European journal of pharmacology. 2011 Oct; 668(1-2):337-9. doi: 10.1016/j.ejphar.2011.06.040. [PMID: 21756896]
  • Yi Liu, Zong Bao Wang, Wei Dong Yin, Qin Kai Li, Man Bo Cai, Jian Yu, Hong Guang Li, Chi Zhang, Xiu Hong Zu. Preventive effect of Ibrolipim on suppressing lipid accumulation and increasing lipoprotein lipase in the kidneys of diet-induced diabetic minipigs. Lipids in health and disease. 2011 Jul; 10(?):117. doi: 10.1186/1476-511x-10-117. [PMID: 21762526]
  • Juryoun Soh, Dae Young Kwon, Youn-Soo Cha. Hepatic gene expression profiles are altered by dietary unsalted korean fermented soybean (chongkukjang) consumption in mice with diet-induced obesity. Journal of nutrition and metabolism. 2011; 2011(?):260214. doi: 10.1155/2011/260214. [PMID: 21437188]
  • Qinkai Li, Weidong Yin, Manbo Cai, Yi Liu, Hongjie Hou, Qingyun Shen, Chi Zhang, Junxia Xiao, Xiaobo Hu, Qishisan Wu, Makoto Funaki, Yutaka Nakaya. NO-1886 suppresses diet-induced insulin resistance and cholesterol accumulation through STAT5-dependent upregulation of IGF1 and CYP7A1. The Journal of endocrinology. 2010 Jan; 204(1):47-56. doi: 10.1677/joe-09-0278. [PMID: 19815588]
  • Xin Ma, Yan-Wei Hu, Zhong-Cheng Mo, Xiao-Xu Li, Xie-Hong Liu, Ji Xiao, Wei-Dong Yin, Duan-Fang Liao, Chao-Ke Tang. NO-1886 up-regulates Niemann-Pick C1 protein (NPC1) expression through liver X receptor alpha signaling pathway in THP-1 macrophage-derived foam cells. Cardiovascular drugs and therapy. 2009 Jun; 23(3):199-206. doi: 10.1007/s10557-009-6165-8. [PMID: 19229602]
  • Jun Yu, Eagle S H Chu, Alex Y Hui, Kin F Cheung, Henry L Y Chan, Wai K Leung, Geoffrey C Farrell, Joseph J Y Sung. Lipoprotein lipase activator ameliorates the severity of dietary steatohepatitis. Biochemical and biophysical research communications. 2007 Apr; 356(1):53-9. doi: 10.1016/j.bbrc.2007.02.129. [PMID: 17350593]
  • Chi Zhang, Weidong Yin, Duanfang Liao, Liang Huang, Chaoke Tang, Kazuhiko Tsutsumi, Zongbao Wang, Yi Liu, Qinkai Li, Hongjie Hou, Manbo Cai, Junxia Xiao. NO-1886 upregulates ATP binding cassette transporter A1 and inhibits diet-induced atherosclerosis in Chinese Bama minipigs. Journal of lipid research. 2006 Sep; 47(9):2055-63. doi: 10.1194/jlr.m600226-jlr200. [PMID: 16807312]
  • Manbo Cai, Weidong Yin, Qinkai Li, Duanfang Liao, Kazuhiko Tsutsumi, Hongjie Hou, Yi Liu, Chi Zhang, Jianjun Li, Zongbao Wang, Junxia Xiao. Effects of NO-1886 on inflammation-associated cytokines in high-fat/high-sucrose/high-cholesterol diet-fed miniature pigs. European journal of pharmacology. 2006 Jul; 540(1-3):139-46. doi: 10.1016/j.ejphar.2006.04.032. [PMID: 16730700]
  • Michihiro Mutoh, Naoko Niho, Keiji Wakabayashi. Concomitant suppression of hyperlipidemia and intestinal polyp formation by increasing lipoprotein lipase activity in Apc-deficient mice. Biological chemistry. 2006 Apr; 387(4):381-5. doi: 10.1515/bc.2006.051. [PMID: 16606335]
  • Seiichiro Kano, Masako Doi. NO-1886 (ibrolipim), a lipoprotein lipase-promoting agent, accelerates the expression of UCP3 messenger RNA and ameliorates obesity in ovariectomized rats. Metabolism: clinical and experimental. 2006 Feb; 55(2):151-8. doi: 10.1016/j.metabol.2005.08.007. [PMID: 16423620]
  • Yujiro Morioka, Masuhiro Nishimura, Teruko Imai, Satoshi Suzuki, Miwa Harada, Tetsuo Satoh, Shinsaku Naito. Assessment of induction of cytochrome P450 by NO-1886 (ibrolipim), a lipoprotein lipase-promoting agent, in primary cultures of human hepatocytes and in female rat liver. Drug metabolism and pharmacokinetics. 2006 Feb; 21(1):19-28. doi: 10.2133/dmpk.21.19. [PMID: 16547390]
  • Masataka Kusunoki, Kazuhiko Tsutsumi, Koshi Iwata, Weidong Yin, Takao Nakamura, Hitoshi Ogawa, Tomoko Nomura, Koya Mizutani, Arao Futenma, Keiko Utsumi, Tetsuro Miyata. NO-1886 (ibrolipim), a lipoprotein lipase activator, increases the expression of uncoupling protein 3 in skeletal muscle and suppresses fat accumulation in high-fat diet-induced obesity in rats. Metabolism: clinical and experimental. 2005 Dec; 54(12):1587-92. doi: 10.1016/j.metabol.2005.06.005. [PMID: 16311090]
  • Naoko Niho, Michihiro Mutoh, Mami Takahashi, Kazuhiko Tsutsumi, Takashi Sugimura, Keiji Wakabayashi. Concurrent suppression of hyperlipidemia and intestinal polyp formation by NO-1886, increasing lipoprotein lipase activity in Min mice. Proceedings of the National Academy of Sciences of the United States of America. 2005 Feb; 102(8):2970-4. doi: 10.1073/pnas.0500153102. [PMID: 15710887]
  • Weidong Yin, Duanfang Liao, Zongbao Wang, Shoumin Xi, Kazuhiko Tsutsumi, Tomonari Koike, Jianglin Fan, Guanghui Yi, Qiuju Zhang, Zhonghua Yuan, Kechao Tang. NO-1886 inhibits size of adipocytes, suppresses plasma levels of tumor necrosis factor-alpha and free fatty acids, improves glucose metabolism in high-fat/high-sucrose-fed miniature pigs. Pharmacological research. 2004 Mar; 49(3):199-206. doi: 10.1016/j.phrs.2003.09.008. [PMID: 14726214]
  • W Yin, D Liao, M Kusunoki, S Xi, K Tsutsumi, Z Wang, X Lian, T Koike, J Fan, Y Yang, C Tang. NO-1886 decreases ectopic lipid deposition and protects pancreatic beta cells in diet-induced diabetic swine. The Journal of endocrinology. 2004 Mar; 180(3):399-408. doi: 10.1677/joe.0.1800399. [PMID: 15012594]
  • Masataka Kusunoki, Kazuhiko Tsutsumi, Yasuhide Inoue, Tsutomu Hara, Tetsuo Miyata, Takao Nakamura, Hitoshi Ogawa, Fumihiko Sakakibara, Yoshitaka Fukuzawa, Naomi Okabayashi, Koich Kato, Hiroshi Ikeda, Tsuyoshi Kurokawa, Tetsuro Ishikawa, Kazuo Otake, Yutaka Nakaya. Lipoprotein lipase activator NO-1886 improves fatty liver caused by high-fat feeding in streptozotocin-induced diabetic rats. Metabolism: clinical and experimental. 2004 Feb; 53(2):260-3. doi: 10.1016/j.metabol.2003.08.016. [PMID: 14767881]
  • Y Morioka, M Harada, T Imai, S Naito. Pharmacokinetics and metabolism of NO-1886, a lipoprotein lipase-promoting agent, in cynomolgus monkey. Xenobiotica; the fate of foreign compounds in biological systems. 2003 Dec; 33(12):1247-60. doi: 10.1080/00498250310001646344. [PMID: 14742146]
  • K Tsutsumi. Lipoprotein lipase and atherosclerosis. Current vascular pharmacology. 2003 Mar; 1(1):11-7. doi: 10.2174/1570161033386673. [PMID: 15320848]
  • Weidong Yin, Kazuhiko Tsutsumi. Lipoprotein lipase activator NO-1886. Cardiovascular drug reviews. 2003; 21(2):133-42. doi: 10.1111/j.1527-3466.2003.tb00111.x. [PMID: 12847564]
  • Weidong Yin, Zhonghua Yuan, Kazuhiko Tsutsumi, Yuxiang Xie, Qiuju Zhang, Zongbao Wang, Guoxiang Fu, Guang Long, Yongzong Yang. A lipoprotein lipase-promoting agent, NO-1886, improves glucose and lipid metabolism in high fat, high sucrose-fed New Zealand white rabbits. International journal of experimental diabesity research. 2003 Jan; 4(1):27-34. doi: 10.1080/15438600303732. [PMID: 12745668]
  • Masataka Kusunoki, Kazuhiko Tsutsumi, Tsutomu Hara, Hitoshi Ogawa, Takao Nakamura, Tetsuro Miyata, Fumihiko Sakakibara, Yoshitaka Fukuzawa, Takashi Suga, Shinich Kakumu, Yutaka Nakaya. A lipoprotein lipase activator, NO-1886 prevents impaired endothelium-dependent relaxation of aorta caused by exercise in aged rats. Experimental gerontology. 2002 Jul; 37(7):891-6. doi: 10.1016/s0531-5565(02)00023-2. [PMID: 12086697]
  • Masataka Kusunoki, Kazuhiko Tsutsumi, Tsutomu Hara, Hitoshi Ogawa, Takao Nakamura, Tetsuro Miyata, Fumihiko Sakakibara, Yoshitaka Fukuzawa, Takashi Suga, Shinichi Kakumu, Yutaka Nakaya. Correlation between lipid and glycogen contents in liver and insulin resistance in high-fat-fed rats treated with the lipoprotein lipase activator NO-1886. Metabolism: clinical and experimental. 2002 Jun; 51(6):792-5. doi: 10.1053/meta.2002.32732. [PMID: 12037738]
  • Yujiro Morioka, Makiko Otsu, Shinsaku Naito, Teruko Imai. Phosphonate O-deethylation of [4-(4-bromo-2-cyano-phenylcarbamoyl) benzyl]-phosphonic acid diethyl ester, a lipoprotein lipase-promoting agent, catalyzed by cytochrome P450 2C8 and 3A4 in human liver microsomes. Drug metabolism and disposition: the biological fate of chemicals. 2002 Mar; 30(3):301-6. doi: 10.1124/dmd.30.3.301. [PMID: 11854149]
  • Weidong Yin, Kazuhiko Tsutsumi, Zhonghua Yuan, Baotang Yang. Effects of the lipoprotein lipase activator NO-1886 as a suppressor agent of atherosclerosis in aorta of mild diabetic rabbits. Arzneimittel-Forschung. 2002; 52(8):610-4. doi: 10.1055/s-0031-1299939. [PMID: 12236049]
  • Y Hirakawa, H Shimokawa. [Lipid-lowering drugs]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica. 2001 Dec; 118(6):389-95. doi: 10.1254/fpj.118.389. [PMID: 11778457]
  • M Kusunoki, T Hara, K Tsutsumi, T Nakamura, T Miyata, F Sakakibara, S Sakamoto, H Ogawa, Y Nakaya, L H Storlien. The lipoprotein lipase activator, NO-1886, suppresses fat accumulation and insulin resistance in rats fed a high-fat diet. Diabetologia. 2000 Jul; 43(7):875-80. doi: 10.1007/s001250051464. [PMID: 10952460]
  • K Nakayama, T Hara, M Kusunoki, K Tsutsumi, A Minami, K Okada, S Sakamoto, M Ohnaka, T Miyata, T Nakamura, T Aoki, A Fukatsu, Y Nakaya, S Kakumu. Effect of the lipoprotein lipase activator NO-1886 on adriamycin-induced nephrotic syndrome in rats. Metabolism: clinical and experimental. 2000 May; 49(5):588-93. doi: 10.1016/s0026-0495(00)80032-3. [PMID: 10831167]
  • K Tsutsumi, Y Inoue, T Murase. Effects of NO-1886, a lipoprotein lipase promoting agent, on homozygous and heterozygous Watanabe heritable hyperlipidaemic rabbits. Arzneimittel-Forschung. 2000 Feb; 50(2):118-21. doi: 10.1055/s-0031-1300175. [PMID: 10719613]
  • I Kawamura, N Yamamoto, F Sakai, H Yamazaki, T Goto. Effect of lipoprotein lipase activators bezafibrate and NO-1886, on B16 melanoma-induced cachexia in mice. Anticancer research. 1999 Sep; 19(5B):4099-103. doi: ". [PMID: 10628360]
  • T Hara, M Kusunoki, K Tsutsumi, K Okada, S Sakamoto, M Ohnaka, T Nakamura, T Miyata, K Nakayama, A Fukatsu, K Kato, S Kakumu, Y Nakaya. A lipoprotein lipase activator, NO-1886, improves endothelium-dependent relaxation of rat aorta associated with aging. European journal of pharmacology. 1998 May; 350(1):75-9. doi: 10.1016/s0014-2999(98)00230-1. [PMID: 9683017]
  • T Hara, D Cameron-Smith, G J Cooney, M Kusunoki, K Tsutsumi, L H Storlien. The actions of a novel lipoprotein lipase activator, NO-1886, in hypertriglyceridemic fructose-fed rats. Metabolism: clinical and experimental. 1998 Feb; 47(2):149-53. doi: 10.1016/s0026-0495(98)90211-6. [PMID: 9472961]
  • M Ohara, K Tsutsumi, N Ohsawa. Suppression of carcass weight loss in cachexia in rats bearing Leydig cell tumor by the novel compound NO-1886, a lipoprotein lipase activator. Metabolism: clinical and experimental. 1998 Jan; 47(1):101-5. doi: 10.1016/s0026-0495(98)90201-3. [PMID: 9440486]
  • T Chiba, S Miura, F Sawamura, R Uetsuka, I Tomita, Y Inoue, K Tsutsumi, T Tomita. Antiatherogenic effects of a novel lipoprotein lipase-enhancing agent in cholesterol-fed New Zealand white rabbits. Arteriosclerosis, thrombosis, and vascular biology. 1997 Nov; 17(11):2601-8. doi: 10.1161/01.atv.17.11.2601. [PMID: 9409232]
  • A Hagi, I Hirai, H Kohri, K Tsutsumi. The novel compound NO-1886 activates lipoprotein lipase in primary cultured adipose and skeletal muscle cells. Biological & pharmaceutical bulletin. 1997 Oct; 20(10):1108-10. doi: 10.1248/bpb.20.1108. [PMID: 9353574]
  • K Tsutsumi, Y Inoue, A Hagi, T Murase. The novel compound NO-1886 elevates plasma high-density lipoprotein cholesterol levels in hamsters and rabbits by increasing lipoprotein lipase without any effect on cholesteryl ester transfer protein activity. Metabolism: clinical and experimental. 1997 Mar; 46(3):257-60. doi: 10.1016/s0026-0495(97)90250-x. [PMID: 9054466]
  • K Tsutsumi, Y Inoue, C Yoshida. Suppression of hyperlipidemia-associated cataracts in diabetic rats with the lipoprotein lipase activator NO-1886. Biological & pharmaceutical bulletin. 1996 Dec; 19(12):1570-3. doi: 10.1248/bpb.19.1570. [PMID: 8996641]
  • Y Morioka, M Ohmizo, M Harada, K Goto, S Naito, K Tsutsumi. Metabolism of diethyl 4-[(4-bromo-2-cyanophenyl)-carbamoyl]benzylphosphonate in the rat. Xenobiotica; the fate of foreign compounds in biological systems. 1996 Aug; 26(8):853-61. doi: 10.3109/00498259609046755. [PMID: 8879149]
  • K Goto, S Nakamura, Y Morioka, M Kondo, S Naito, K Tsutsumi. Synthesis and biological activity of the metabolites of diethyl 4-[(4-bromo-2-cyanophenyl)carbamoyl]benzylphosphonate (NO-1886). Chemical & pharmaceutical bulletin. 1996 Mar; 44(3):547-51. doi: 10.1248/cpb.44.547. [PMID: 8882452]
  • K Tsutsumi, Y Inoue, A Shima, T Murase. Correction of hypertriglyceridemia with low high-density lipoprotein cholesterol by the novel compound NO-1886, a lipoprotein lipase-promoting agent, in STZ-induced diabetic rats. Diabetes. 1995 Apr; 44(4):414-7. doi: 10.2337/diab.44.4.414. [PMID: 7698509]
  • K Tsutsumi, Y Inoue, A Shima, K Iwasaki, M Kawamura, T Murase. The novel compound NO-1886 increases lipoprotein lipase activity with resulting elevation of high density lipoprotein cholesterol, and long-term administration inhibits atherogenesis in the coronary arteries of rats with experimental atherosclerosis. The Journal of clinical investigation. 1993 Jul; 92(1):411-7. doi: 10.1172/jci116582. [PMID: 8326009]